The kidney as part of the cardiovascular system

Journal of Cardiovascular Pharmacology

Volumn 33, Issue SUPPL. 1, 1999, Pages

  Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Atherosclerosis; Cardiovascular risk; Nephrosclerosis; Renal vascular damage

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CREATININE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY CONCENTRATING CAPACITY; KIDNEY FAILURE; KIDNEY INJURY; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0032910820     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199900001-00002     Document Type: Conference Paper

References (50)

1. Woolfson RG, De Wordener HE. Primary renal abnormalities in hereditary hypertension. Kidney Int 1996;50:717-31.
2. Ruilope LM, Lahera V, Rodicio JL, Romero JC. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994;23:3-9.
3. Folkow B. Kidneys in primary hypertension initiators, stabilizers or/and victim-aggravators? Blood Pressure 1994;3:212-5.
4. Ruilope LM. How much does the kidney participate in the origin of primary hypertension? Blood Pressure 1994;3:216-8.
5. Blackshear JL, Garnic D, Williams GH, Harrington DP, Holenberg NK. Exaggerated renal vasodilator response to calcium entry blockade in first-degree relatives of essential hypertensive subjects. Hypertension 1987;9:384-9.
6. Montanari A, Vallisa D, Ragni G, et al. Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. Hypertension 1988;12:498-505.
7. Ramírez AJ, Giménez MI, Gallo G, Marco EJ, Sánchez RA. Renal sodium handling abnormalities in hypertensive and normotensive patients with a family history of hypertension. J Hypertens 1989;7(Suppl 6):S178-9.
8. Ruilope LM, Campo C, Rodicio JL. Relationship between blood pressure and renal function. J Hypertens 1994;12(Suppl 8):S55-9.
9. Perera GA. Hypertensive vascular disease: description and natural history. J Chron Dis 1995;1:33-42.
10. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-38.
11. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, ed. Textbook of hypertension. London, Blackwell Scientific, 1994:1156-64.
12. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal failure? Kidney Int 1992;41(Suppl 36):S33-7.
13. Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995;345:749-51.
14. National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System: annual data report. Bethesda, MD: National Institutes of Health, 1989.
15. Ruilope LM, Alcazar JM, Rodicio JL. Renal consequences of arterial hypertension. J Hypertens 1992;10(Suppl 7):S85-90.
16. Ruilope LM, Alcázar JM, Hernández E, Moreno F, Martínez MA, Rodicio JL. Does an adequate control of blood pressure protect the kidney in essential hypertension. J Hypertens 1990;8:525-32.
17. Rostand SG, Brown G, Kirk K, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320:684-8.
18. Rosansky SJ, Hoover DR, King I, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 1990;150:2073-6.
19. Perneger TV, Nieto RJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine. Results from the "Clue" Study and the ARIC Study. JAMA 1993;269:488-93.
20. Perneger TV, Klag MJ, Feldman HI, Whelton PK. Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 1993;269:1272-7.
21. Samuelsson O. Hypertension in middle-aged man: management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand 1985;702(Suppl):1-79.
22. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;2:1053-8.
23. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 1989;13(Suppl I):I80-93.
24. Aronow WS. Usefulness of serum creatinine as a marker for coronary events in elderly patients with either systemic hypertension or diabetes mellitus. Am J Cardiol 1991;68:476-7.
25. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetes Med 1995;12:149-55.
26. Takazakura E, Sawabu N, Handa A, Takada A, Shinoda A, Takeuchi J. Intrarenal vascular changes with age and disease. Kidney Int 1972;2:224-30.
27. Tracy RE, Bhandaru SY, Oalmann MC, Guzmán MA, Newman WP III. Blood pressure and nephrosclerosis in black and white men and women aged 25 to 54. Mod Pathol 1991;4:602-9.
28. Tracy RE, Malcom GT, Oalmann MC, Newman WI, Guzmán MA, Strong GP. Nephrosclerosis in coronary heart disease. Mod Pathol 1994;7:301-9.
29. Tracy RE, Strong JP, Newman WP III, Malcom GT, Oalmann MC, Guzman MA. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25-54 years. Kidney Int 1996;49:564-70.
30. Ruilope LM, Rodicio JL. Microalbuminuria in clinical practice. Kidney: A Current Survey of World Literature 1995;4:211-6.
31. Agrawal B, Berger A, Wolf K, Luft FC. Microalbumin screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996;14(Suppl 2):223-8.
32. Cerasola G, Cottone S, Mulé G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996;14:921-6.
33. Ljingman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion - a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996;9:770-8.
34. Tierney WM, Harris LE, Copley JB, Luft FC. Effect of hypertension and type II diabetes on renal function in an urban population. Am J Hypertens 1990;3:69-75.
35. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno CG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980;93:817-21.
36. Reaven GM, Lithell H, Landsberg L. Mechanisms of disease: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-81.
37. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity - insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995;142:288-94.
38. Ruilope LM, Alcazar JM, Hernandez E, et al. Metabolic alterations accompanying essential hypertension are associated with nephrosclerosis [Abstract], J Hypertens 1993;11(Suppl 5):S475.
39. Dengel D, Goldberg AP, Mayuga RS, Kairis GM, Weir MR. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 1996;28:127-32.
40. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995;48: 851-9.
41. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
42. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989;35:670-4.
43. Ruilope LM, Hanson L, Zanchetti A, for the HOT Study Group. Renal aspects of the HOT Study. J Nephrol 1996;9:147-51.
44. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
45. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
46. Ruilope LM, Alcazar JM, Hernandez E, Praga M, Lahera V, Rodicio JL. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994;45(Suppl):S171-3.
47. Sihm I, Shroeder AP, Aalkjaer C, et al. Regression of media-tolumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor based regimen in hypertensive patients. Am J Cardiol 1995;76:38E-40E.
48. Schriffrin EL, Deng LY. Comparison of the effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995;25:699-703.
49. Himmelmann A, Hansson L, Hansson BG, et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Pressure 1995;4:85-90.
50. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.